Skip to main content
Deciphera to seek FDA approval for ripretinib for GIST
8/14/2019

Deciphera Pharmaceuticals announced its intent to file for regulatory approval with the FDA for its drug candidate ripretinib as a treatment for gastrointestinal stromal tumors. The filing will be supported by data from its late-stage trial, which resulted in an 85% decrease in risk for disease progress or mortality among GIST patients who had not responded to three prior therapies.

Full Story: